Epidemiological Study In Hypertensive Patients: Assessment Of Risk Factors Prevalence And Of Patients' Management

Completed

• Conditions: Hypertension
• Interventions: Other: Usual Care

• Registration Number: NCT00709787
• Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Brief Summary

To assess the pattern of hypertension in the population in terms of presence of additional risk factors (ARF) and cardiovascular risk stratification.

Detailed Description

routine physician visits

Study Timeline

• Study Start: 2008-06
• Study First Submitted: 2008-07-01
• Study First Submitted QC: 2008-07-01
• Study First Posted: 2008-07-03
• Primary Completion: 2009-02
• Study Completion: 2009-02
• Status Verified: 2021-01
• Last Update Submitted: 2021-01-26
• Last Update Posted: 2021-01-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 899

Inclusion Criteria

• Age 18 to 80 years old
• Patients with hypertension: newly diagnosed and /or already diagnosed and treated , whether at goal or not for the blood pressure level;
• Patients with no history of CHD/CVD

Exclusion Criteria

• None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Hypertensive Subjects undergoing primary prevention	Usual Care	-

Primary Outcome Measures

Name	Time	Method
Description of hypertensive patients in terms of presence of associated cardiovascular (CV) risk factors (number of additional CV risk factors and frequency)

Secondary Outcome Measures

Name	Time	Method
Description of pattern of management of HT and CVD prevention, through lifestyle and use of drug therapies,
Estimate adherence to treatment using the Morisky Adherence Scale (MAS)
Estimation of hypertensive patients CV risk stratification based on ESH/ESC Hypertension Guidelines 2007 and to compare it with physicians' estimation of CV risk.

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇨🇿 Prague 4, Czechia